Palvella Therapeutics (NASDAQ:PVLA) Receives Consensus Rating of “Buy” from Analysts

Shares of Palvella Therapeutics (NASDAQ:PVLA) have been given an average recommendation of “Buy” by the seven brokerages that are covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $43.50.

Several research analysts recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating for the company. TD Cowen assumed coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They set a “buy” rating and a $44.00 target price for the company. Stifel Nicolaus assumed coverage on Palvella Therapeutics in a research note on Wednesday, March 26th. They issued a “buy” rating and a $45.00 price target on the stock. Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Finally, Jones Trading initiated coverage on shares of Palvella Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $45.00 target price on the stock.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $27.99 on Tuesday. The business has a fifty day moving average of $20.54. The stock has a market cap of $314.08 million, a price-to-earnings ratio of -2.31 and a beta of 0.54. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27.

Hedge Funds Weigh In On Palvella Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. BML Capital Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter worth $506,000. Frazier Life Sciences Management L.P. acquired a new stake in Palvella Therapeutics during the 4th quarter worth approximately $7,847,000. Cresset Asset Management LLC purchased a new position in Palvella Therapeutics in the 4th quarter valued at approximately $251,000. Suvretta Capital Management LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter worth $8,574,000. Finally, DAFNA Capital Management LLC purchased a new stake in shares of Palvella Therapeutics during the fourth quarter worth $857,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.